4.6 Article

Understanding the links between cardiovascular disease and Parkinson's disease

Journal

MOVEMENT DISORDERS
Volume 35, Issue 1, Pages 55-74

Publisher

WILEY
DOI: 10.1002/mds.27836

Keywords

cardiovascular; Parkinson's disease; pathogenesis; risk factors

Funding

  1. NINDS NIH HHS [U01 NS112008, U01 NS082151] Funding Source: Medline
  2. Department of Health [16/167/19] Funding Source: Medline

Ask authors/readers for more resources

Studies investigating the associations between genetic or environmental factors and Parkinson's disease (PD) have uncovered a number of factors shared with cardiovascular disease, either as risk factors or manifestations of cardiovascular disease itself. Older age, male sex, and possibly type 2 diabetes are examples. On the other hand, coffee consumption and physical activity are each associated with a lower risk of both PD and cardiovascular disease. This observation raises questions about the underlying pathophysiological links between cardiovascular disease and PD. There is evidence for common mechanisms in the areas of glucose metabolism, cellular stress, lipid metabolism, and inflammation. On the other hand, smoking and total/low-density lipoprotein cholesterol appear to have opposite associations with cardiovascular disease and PD. Thus, it is uncertain whether the treatment of cardiovascular risk factors will impact on the onset or progression of PD. The available data suggest that a nuanced approach is necessary to manage risk factors such as cholesterol levels once the associations are better understood. Ultimately, the choice of therapy may be tailored to a patient's comorbidity profile. This review presents the epidemiological evidence for both concordant and discordant associations between cardiovascular disease and PD, discusses the cellular and metabolic processes that may underlie these links, and explores the implications this has for patient care and future research. (c) 2019 International Parkinson and Movement Disorder Society

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Quantifying Stridor Associated with Parkinsonism and Deep Brain Stimulation-A Case Report

Timothy Grover, Viswas Dayal, Adrian Fourcin, Catherine Milabo, Patricia Limousin, Thomas Foltynie

MOVEMENT DISORDERS CLINICAL PRACTICE (2022)

Article Cardiac & Cardiovascular Systems

Hourly Air Pollutants and Acute Coronary Syndrome Onset in 1.29 Million Patients

Renjie Chen, Yixuan Jiang, Jialu Hu, Honglei Chen, Huichu Li, Xia Meng, John S. Ji, Ya Gao, Weidong Wang, Cong Liu, Weiyi Fang, Hongbing Yan, Jiyan Chen, Weimin Wang, Dingcheng Xiang, Xi Su, Bo Yu, Yan Wang, Yawei Xu, Lefeng Wang, Chunjie Li, Yundai Chen, Michelle L. Bell, Aaron J. Cohen, Junbo Ge, Yong Huo, Haidong Kan

Summary: This study found that short-term exposure to air pollutants such as PM2.5, NO2, SO2, and CO may trigger the onset of ACS and its subtypes. The associations were strongest in the first hour of exposure and attenuated thereafter.

CIRCULATION (2022)

Review Clinical Neurology

How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?

Philipp Mahlknecht, Thomas Foltynie, Patricia Limousin, Werner Poewe

Summary: A robust body of evidence has established the efficacy of deep brain stimulation (DBS) in reducing off time and dyskinesias in levodopa-treated patients with Parkinson's disease (PD). However, the long-term impact of DBS on the overall progression of disability in PD is less clear.

MOVEMENT DISORDERS (2022)

Article Multidisciplinary Sciences

Olfaction and kidney function in community-dwelling older adults

Keran Wang, Zhehui Luo, Chenxi Li, Jayant M. Pinto, Eric J. Shiroma, Eleanor M. Simonsick, Honglei Chen

Summary: In older adults, poor olfaction is associated with lower kidney function but not future risk of chronic kidney disease (CKD).

PLOS ONE (2022)

Article Otorhinolaryngology

Assessment of Self-reported Sense of Smell, Objective Testing, and Associated Factors in Middle-aged and Older Women

Zichun Cao, Aiwen Yang, Aimee A. D'Aloisio, Lourdes Suarez, Sandra Deming-Halverson, Chenxi Li, Zhehui Luo, Jayant M. Pinto, Emily J. Werder, Dale P. Sandler, Honglei Chen

Summary: Poor olfaction is common in older adults, but often goes unrecognized. This study examined the self-awareness and reporting accuracy of poor olfaction in middle-aged and older women. It found that self-reports of poor olfaction were lower compared to objective tests, and there were significant associations between poor olfaction and factors such as age, marital status, smoking, coffee drinking, obesity, health status, Parkinson disease, cognitive impairment, depression, anxiety, and seasonal allergy.

JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2022)

Article Public, Environmental & Occupational Health

Completeness of cohort-linked US Medicare data: An example from the Agricultural Health Study (1999-2016)

Christine G. Parks, Srishti Shrestha, Stuart Long, Thomas Flottemesch, Sarah Woodruff, Honglei Chen, Gabriella Andreotti, Jonathan N. Hofmann, Laura E. Beane Freeman, Dale P. Sandler

Summary: This article describes the experience of linking the Agricultural Health Study cohort to Medicare claims data and explores the possibility of missing data. The study found that incomplete claims data can lead to a reduced sample size in analyses and that the missingness may not be random.

PREVENTIVE MEDICINE REPORTS (2022)

Article Clinical Neurology

European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies

Gunther Deuschl, Angelo Antonini, Joao Costa, Katarzyna Smilowska, Daniela Berg, Jean-Christophe Corvol, Giovanni Fabbrini, Joaquim Ferreira, Tom Foltynie, Pablo Mir, Annette Schrag, Klaus Seppi, Pille Taba, Evzen Ruzicka, Marianna Selikhova, Nicholas Henschke, Gemma Villanueva, Elena Moro

Summary: This article presents an update on the treatment guidelines for early and advanced Parkinson's disease (PD). The recommended interventions include deep brain stimulation (DBS), brain lesioning, and continuous medication delivery. The evaluation of treatment effects is primarily based on high-level evidence, with clinical consensus used for certain specific situations.

MOVEMENT DISORDERS (2022)

Article Multidisciplinary Sciences

Depressive symptoms before and after Parkinson's diagnosis-A longitudinal analysis

Shengfang Song, Zhehui Luo, Chenxi Li, Xuemei Huang, Eric J. Shiroma, Eleanor M. Simonsick, Honglei Chen

Summary: This study longitudinally assessed depressive symptoms in older adults with Parkinson's disease (PD) and found that depressive symptoms start to increase a few years prior to PD diagnosis and become significantly different from expected levels one year before diagnosis.

PLOS ONE (2022)

Article Otorhinolaryngology

Associations of Prior Head Injury With Olfaction in Older Adults Results From the Atherosclerosis Risk in Communities (ARIC) Study

Andrea L. C. Schneider, Rebecca F. Gottesman, Thomas H. Mosley, Srishti Shrestha, Nicholas R. Rowan, A. Richey Sharrett, Honglei Chen, Vidyulata Kamath

Summary: The study found an association between head injury and olfactory dysfunction, particularly in individuals with multiple prior head injuries and more severe head injury. The findings also suggested that individuals with prior head injury were more likely to underestimate or overestimate their olfactory deficits compared to objective olfactory testing.

JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2022)

Article Neurosciences

Computer vision quantification of whole-body Parkinsonian bradykinesia using a large multi-site population

Gareth Morinan, Yuriy Dushin, Grzegorz Sarapata, Samuel Rupprechter, Yuwei Peng, Christine Girges, Maricel Salazar, Catherine Milabo, Krista Sibley, Thomas Foltynie, Ioana Cociasu, Lucia Ricciardi, Fahd Baig, Francesca Morgante, Louise-Ann Leyland, Rimona S. Weil, Ro'ee Gilron, Jonathan O'Keeffe

Summary: Parkinson's disease is a common neurological disorder characterized by bradykinesia. Using computer vision to objectively quantify bradykinesia could standardize decision-making for treatment and clinical trials, as well as facilitate remote assessment.

NPJ PARKINSONS DISEASE (2023)

Article Clinical Neurology

Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease

Tom Foltynie, Sonia Gandhi, Cristina Gonzalez-Robles, Marie-Louise Zeissler, Georgia Mills, Roger Barker, James Carpenter, Anette Schrag, Anthony Schapira, Oliver Bandmann, Stephen Mullin, Joy Duffen, Kevin McFarthing, Jeremy Chataway, Mahesh Parmar, Camille Carroll

Summary: Multi-arm, multi-stage platform designs have improved the efficiency of clinical trials in the field of oncology. Foltynie et al. discuss the challenges and considerations of using this approach to assess potential disease-modifying treatments in progressive neurological conditions such as Parkinson's disease.

BRAIN (2023)

Letter Clinical Neurology

Confusion of Evidence-Based Reviews and Guidelines

Guenther Deuschl, Angelo Antonini, Joao Costa, Katarzyna Smilowska, Daniela Berg, Jean-Christophe Corvol, Giovanni Fabbrini, Joaquim Ferreira, Tom Foltynie, Pablo Mir, Anette Schrag, Klaus Seppi, Pille Taba, Evzen Ruzicka, Marianna Selikhova, Nicholas Henschke, Gemma Villanueva, Elena Moro

MOVEMENT DISORDERS (2023)

Article Neurosciences

Effects of deep brain stimulation frequency on eye movements and cognitive control

Andre Zacharia, Diego Kaski, Walid Bouthour, Viswas Dayal, Matthieu Bereau, Philipp Mahlknecht, Dejan Georgiev, Julie Peron, Tom Foltynie, Ludvic Zrinzo, Marjan Jahanshahi, John Rothwell, Patricia Limousin

Summary: This study investigated the effects of 80 Hz vs. 130 Hz frequency STN-DBS on eye movements and executive control in Parkinson's disease patients. The results showed that 80 Hz STN-DBS reduced the ability to maintain stable fixation, resulting in a higher antisaccade error rate, without affecting inhibition or motor state.

NPJ PARKINSONS DISEASE (2023)

Review Clinical Neurology

How should we be using biomarkers in trials of disease modification in Parkinson's disease?

Nirosen Vijiaratnam, Thomas Foltynie

Summary: The recent validation of the alpha-synuclein seed amplification assay as a biomarker for the diagnosis of Parkinson's disease has provided a basis for a proposed staging system in clinical studies. However, further challenges exist in finding biomarkers for disease modifying agents, including optimizing distinction between different alpha-synucleinopathies and predicting clinical benefit. The use of additional biomarkers, such as CSF proteins and imaging techniques, may enhance trial planning and assessment of interventions.

BRAIN (2023)

No Data Available